国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (3): 224-227.doi: 10.3760/cma.j.issn.1673422X.2015.03.017

• 综述 • 上一篇    下一篇

Akt抑制剂及其在结直肠癌治疗中的研究现状

刁存启,毕经旺,王宝成   

  1. 250031济南军区总医院肿瘤科
  • 出版日期:2015-03-08 发布日期:2015-01-29
  • 通讯作者: 毕经旺，Email： jingwangbi@live.cn E-mail:jingwangbi@live.cn

Akt inhibitors in the treatment of colorectal cancer

Diao Cunqi, Bi Jingwang， Wang Baocheng   

  1. Department of Oncology, The General Hospital of Ji′nan Military Command, Ji′nan 250031, China
  • Online:2015-03-08 Published:2015-01-29
  • Contact: Bi Jingwang E-mail:jingwangbi@live.cn

PDF

1423

被引次数

1

摘要： 蛋白激酶B（Akt）是PI3KAktmTOR信号通路中的一个中间信号分子，其异常活化在结直肠癌的发生发展中起到重要的作用，以此为靶点的药物已成为结直肠癌治疗的研究热点，临床试验研究证明，针对Akt为靶点的多种抑制剂具有较好的抗肿瘤活性。近年来，有关Akt抑制剂和其在结直肠癌治疗中的研究也越来越受到重视。

关键词: 结直肠肿瘤, 靶向治疗, PI3KAktmTOR信号通路

Abstract: Protein kinase B(Akt) is an intermediate signal molecule in PI3KAktmTOR signaling pathway which plays an important role in development and incidence of colorectal cancer when activated by phosphorylation. As target of drugs, Akt has become a focus in the treatment of colorectal cancer. Clinical trials research proves that many kinds of Akt inhibitors have good antitumor activity. In recent years, the Akt inhibitors are more and more be taken seriously in colorectal cancer treatment.

Key words: Colorectal neoplasms, Targeted therapy, PI3KAktmTOR signal pathway